StockMarketWire.com - Liquid biopsy company Angle said the University of Birmingham had published research indicating the potential of using CTC liquid biopsies to improve treatment of head and neck cancer and found that the company's liquid biopsy system held key advantages over other liquid biopsy systems.

Key advantages of Angle's Parsortix system, over traditional tissue biopsies, included the ability to repeat the investigation at multiple time points and a reduction in overall healthcare costs, according to the research published by the University of Birmingham.

'Identified advantages of the Parsortix system, over other CTC liquid biopsy systems, are that it is not antibody-dependent and is able to detect all sub-populations of CTCs as well as CTC clusters,' the research noted. 'Other liquid biopsy approaches have been shown to have significant limitations in this indication. '

At 9:55am: [LON:AGL] Angle PLC share price was -1p at 76p



Story provided by StockMarketWire.com